A Phase 1 Single Center, Non-randomized Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Refractory Diffuse Large B-cell Lymphoma

Trial Profile

A Phase 1 Single Center, Non-randomized Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Refractory Diffuse Large B-cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Acronyms CARD-1
  • Sponsors Cellular Biomedicine Group
  • Most Recent Events

    • 01 Dec 2016 New trial record
    • 29 Nov 2016 According to Cellular Biomedicine media release, final data expected to be available in the second half of 2017.
    • 29 Nov 2016 Status changed from not yet recruiting to recruiting, as per Cellular Biomedicine media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top